Cardiac overexpression of constitutively active Galpha q causes angiotensin II type1 receptor activation, leading to progressive heart failure and ventricular arrhythmias in transgenic mice

• Published in: PloS one Vol. 9; no. 8; p. e106354
• Main Authors: Matsushita, Naoko, Kashihara, Toshihide, Shimojo, Hisashi, Suzuki, Satoshi, Nakada, Tsutomu, Takeishi, Yasuchika, Mende, Ulrike, Taira, Eiichi, Yamada, Mitsuhiko, Sanbe, Atsushi, Hirose, Masamichi
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 29.08.2014; Public Library of Science (PLoS)
• Subjects: Action potential; Activation; Adaptor Proteins, Signal Transducing - genetics; Adaptor Proteins, Signal Transducing - metabolism; Angiotensin AT1 receptors; Angiotensin II; Angiotensins; Animal experimentation; Animals; Arrhythmia; Atrial Natriuretic Factor - metabolism; Blood pressure; Collagen; Collagen (type I); Collagen Type I - metabolism; Connective tissue growth factor; Contraction; Disease Models, Animal; EKG; Electrocardiography; Fibrosis; Gene expression; Gene Expression Regulation - drug effects; Genetic engineering; GTP-Binding Protein alpha Subunits, Gq-G11 - genetics; Heart; Heart diseases; Heart failure; Heart Failure - genetics; Heart Failure - physiopathology; Heart Failure - prevention & control; Hypertrophy; Imidazoles - administration & dosage; Kinases; Major histocompatibility complex; Medicine and Health Sciences; Mice; Mice, Transgenic; Myosin Heavy Chains - metabolism; Peptidyl-dipeptidase A; Proteins; Receptor mechanisms; Rodents; Tetrazoles - administration & dosage; Transgenic mice; Transient receptor potential proteins; Ventricle; Ventricular Premature Complexes - genetics; Ventricular Premature Complexes - physiopathology; Ventricular Premature Complexes - prevention & control; Rhode Island; United States > US; Japan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0106354

Transgenic mice with transient cardiac expression of constitutively active Galpha q (Gαq-TG) exhibt progressive heart failure and ventricular arrhythmias after the initiating stimulus of transfected constitutively active Gαq becomes undetectable. However, the mechanisms are still unknown. We examined the effects of chronic administration of olmesartan on heart failure and ventricular arrhythmia in Gαq-TG mice. Olmesartan (1 mg/kg/day) or vehicle was chronically administered to Gαq-TG from 6 to 32 weeks of age, and all experiments were performed in mice at the age of 32 weeks. Chronic olmesartan administration prevented the severe reduction of left ventricular fractional shortening, and inhibited ventricular interstitial fibrosis and ventricular myocyte hypertrophy in Gαq-TG. Electrocardiogram demonstrated that premature ventricular contraction (PVC) was frequently (more than 20 beats/min) observed in 9 of 10 vehicle-treated Gαq-TG but in none of 10 olmesartan-treated Gαq-TG. The collected QT interval and monophasic action potential duration in the left ventricle were significantly shorter in olmesartan-treated Gαq-TG than in vehicle-treated Gαq-TG. CTGF, collagen type 1, ANP, BNP, and β-MHC gene expression was increased and olmesartan significantly decreased the expression of these genes in Gαq-TG mouse ventricles. The expression of canonical transient receptor potential (TRPC) 3 and 6 channel and angiotensin converting enzyme (ACE) proteins but not angiotensin II type 1 (AT1) receptor was increased in Gαq-TG ventricles compared with NTG mouse ventricles. Olmesartan significantly decreased TRPC6 and tended to decrease ACE expressions in Gαq-TG. Moreover, it increased AT1 receptor in Gαq-TG. These findings suggest that angiotensin II type 1 receptor activation plays an important role in the development of heart failure and ventricular arrhythmia in Gαq-TG mouse model of heart failure.